A 63-year-old female is diagnosed with HER2-positive breast cancer. She is started on trastuzumab (Herceptin), a monoclonal antibody targeting HER2 receptors. However, resistance to the drug develops over time. Research suggests that inhibition of a molecular chaperone involved in stabilizing oncogenic proteins may enhance the efficacy of cancer treatment. Which molecular chaperone is most likely involved in stabilizing oncogenic proteins and is a target for anti-cancer drugs?
